Alembic Pharmaceuticals has received USFDA approval for Azelastine Hydrochloride Ophthalmic Solution used for the treatment of allergic conjunctivitis. The drug is equivalent of Optivar Ophthalmic Solution of Mylan Specialty L P. According to market estimates, Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, has an estimated market size of $8.5 million for 12 months ending December 2018.
Company Profile : Alembic Pharmaceuticals Ltd
Leave a Reply